Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND)
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG
Sponsor: CG Oncology, Inc.
Terminated
Change in study design
Listed as NCT01438112, this PHASE2/PHASE3 trial focuses on Bladder Cancer and Carcinoma in Situ and remains terminated or withdrawn. Sponsored by CG Oncology, Inc., it has been updated 9 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2021 — Jul 2024 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE2_PHASE3
▶ Show 4 earlier versions
-
Feb 2019 — Jun 2020 [monthly]
Terminated PHASE2_PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Terminated PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2_PHASE3
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CG Oncology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .